The ABPI code covers in detail the relationship with patient organisations listed in clause 27 and the related additional information, including a checklist covering the minimum requirements of the written agreement required when a patient organisation cooperates with a pharmaceutical company. The agreement must be certified in accordance with clause 14.3. The industry recognizes that transparency is an important way to build and maintain trust. The application of the Code, including the appeal procedure, is evidence of the industry`s commitment to transparency, as well as the obligation to explain the involvement of pharmaceutical companies in activities and materials and the publication of detailed reports on the cases envisaged by the Code. The industry`s comprehensive agreement on the disclosure of certain data from clinical trials is another example of the industry`s commitment to transparency. Companies must also publish abstracts and results of non-interventional studies as well as the monetary value of certain supports to patient organisations. Other transparency changes that came into effect in 2012 and 2013 included disclosure of the total amount of fees paid to consultants for certain services and the total amounts paid to sponsors` participation in meetings organized by third parties. As provided for in the 2014 Code, from 2015 ongoing transparency will be increased with regard to the advertising of fees and sponsorships for healthcare professionals and healthcare organisations, including the designation of beneficiaries in many cases. Data for 2015 will be published in 2016.
The Code provides for the promotion of medicinal products intended for dispensing to health professionals and other relevant decision-makers. It also contains requirements for interaction with healthcare professionals. It also establishes standards for the provision of information on medicinal products subject to medical prescription to the public and patients, including patient organisations. In addition to the code, there are extensive UK and EU laws on the promotion of medicines. The Code reflects UK law in this area and goes beyond. The objective of the Code is to ensure that the promotion of medicines to healthcare professionals and other relevant decision-makers takes place within a robust framework to support quality patient care. In addition to covering promotional material, it monitors samples, meetings, advertising aids, the provision of medical and educational goods and services, outcome-sharing or risk-sharing agreements, patient access systems, joint work between the pharmaceutical industry and the NHS, the conduct of non-interventional studies, the use of healthcare professionals and other relevant decision-makers as consultants and transfers of to the person and health professionals. other relevant decision-makers and health organizations. The Code also sets standards for the provision of information to patients and the public, as well as for relations with patient groups. . .